The Quantose Insulin Resistance Test for Maternal Insulin Resistance: A Pilot Study

Abstract

Objective Insulin resistance (IR) increases during pregnancy which can lead to hyperinsulinemia, gestational diabetes mellitus (GDM), and neonatal hypoglycemia (NH), especially in obese women. Glucose tolerance testing (GTT) is used clinically to evaluate IR in pregnancy. Quantose IR score index is a novel blood screen of IR validated in nonpregnant individuals. The score is generated using an algorithm that combines insulin and three biomarkers of fatty acid pathways (α-hydroxybutyrate, oleic acid, linoleoyl-glycerophospocholine). Our objective was to determine the validity of Quantose IR test (Metabolan Inc. Morrisville, NC) in assessing IR in pregnant obese women, as compared with the homeostatic model assessment of insulin resistance (HOMA-IR), and its ability to predict GDM and NH.

Study Design Women between 10^0/7 and 13^6/7 weeks of gestation with a pre-pregnancy or early pregnancy body mass index more than 30 kg/m², and no pregestational diabetes, were included. Fasting blood samples were collected at 10^0/7 to 13^6/7 (T1) and 24^0/7 to 28^0/7 (T2) weeks. Quantose IR and HOMA-IR were calculated. All women underwent an early (T1; indicated for women with obesity) and a T2 glucose tolerance tests. GDM was diagnosed using the two-step approach, and NH was defined as a neonatal glucose less than 40 mg/dL in the first 24 hours of life. Linear regression and receiver operating characteristic curves were used for analysis.

Results The trial enrolled 100 patients. Ten subjects (10%) were diagnosed with GDM in the second trimester and none in the first trimester. At T1, Quantose IR (R²= 0.48), but not 1-hour glucose tolerance test (R²= 0.07), correlated with HOMA-IR. Similar correlations were observed at T2. The 1-hour glucose tolerance test followed by HOMA-IR and Quantose IR (area under the curve [AUC]: 0.82, 0.68, and 0.62, respectively) were predictors of GDM. Quantose IR (AUC: 0.74) and 1-hour glucose tolerance test (AUC: 0.72) at T1 and T2 (AUC: 0.75; AUC: 0.93; respectively) were best predictors of NH. The best cut offs, sensitivities, and specificities for prediction of NH were determined.

Conclusion Similar to nonpregnant individuals, Quantose IR appears to be a valid measure of IR in obese pregnant women. First trimester Quantose IR is a predictor of GDM diagnosed in the second trimester and NH. Given that it requires a single blood draw and no glucose challenge, it may be a useful test to evaluate and monitor IR in pregnancy. Our findings may be used as pilot data to explore the potential use of Quantose IR in pregnancy further.

Key Points

• Traditional testing methods for insulin resistance in pregnancy are often performed late, are time consuming, and unpleasant to patients.

• The first trimester one-step Quantose IR test reflects insulin resistance in pregnancy and predicts GDM and neonatal hypoglycemia.

• This is the first known prospective clinical study validating Quantose IR score index in an obstetrical population at risk for developing GDM.

Keywords

insulin resistance - Quantose IR - gestational diabetes - neonatal hypoglycemia

Note

The Quantose test was performed by Metabolan Inc. (Morrisville, NC). However, the company did not have any role in the conduct of the trial, analysis of the data, or drafting of this manuscript.

This study was presented as a poster abstract (1035) at the 40th Society for Maternal–Fetal Medicine Pregnancy meeting February 2020 in Dallas.

Clinical trials registration: Clinicaltrials.gov. Date of submission: December 7, 2017; date of first enrollment: December 22, 2017 (https://clinicaltrials.gov/ct2/show/NCT03388697).

Publication History

Received: 22 June 2020

Accepted: 09 August 2020

Article published online:
07 September 2020

• References

• 1 Ginsberg H, Olefsky JM, Reaven GM. Further evidence that insulin resistance exists in patients with chemical diabetes. Diabetes 1974; 23 (08) 674-678
• 2 Harris MI. Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). Clin Invest Med 1995; 18 (04) 231-239
• 3 Lyssenko V, Jonsson A, Almgren P. et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359 (21) 2220-2232
• 4 Reaven GM, Olefsky JM. The role of insulin resistance in the pathogenesis of diabetes mellitus In: Advances in Metabolic Disorders. Vol 9. Elsevier; 1978: 313-331
• 5 Shen S-W, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970; 49 (12) 2151-2160
• 6 Reaven GM. Insulin resistance and human disease: a short history. J Basic Clin Physiol Pharmacol 1998; 9 (2-4): 387-406
• 7 Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113 (12) 909-915
• 8 Antoniou MC, Gilbert L, Gross J. et al. Potentially modifiable predictors of adverse neonatal and maternal outcomes in pregnancies with gestational diabetes mellitus: can they help for future risk stratification and risk-adapted patient care?. BMC Pregnancy Childbirth 2019; 19 (01) 469
• 9 Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990; 162 (04) 1008-1014
• 10 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237 (03) E214-E223
• 11 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (07) 412-419
• 12 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27 (06) 1487-1495
• 13 Katz A, Nambi SS, Mather K. et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85 (07) 2402-2410
• 14 Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 1995; 346 (8967): 120-121
• 15 Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM. Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care 2001; 24 (09) 1602-1607
• 16 Cobb J, Gall W, Adam K-P. et al. A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol 2013; 7 (01) 100-110
• 17 Cobb J, Eckhart A, Perichon R. et al. A novel test for IGT utilizing metabolite markers of glucose tolerance. J Diabetes Sci Technol 2015; 9 (01) 69-76
• 18 Tripathy D, Cobb JE, Gall W. et al. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab 2015; 100 (05) 1855-1862
• 19 Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 2005; 192 (04) 989-997
• 20 Committee on Obstetric Practice. ACOG Committee Opinion No. 435: postpartum screening for abnormal glucose tolerance in women who had gestational diabetes mellitus. Obstet Gynecol 2009; 113 (06) 1419-1421
• 21 Hale NL, Probst JC, Liu J, Martin AB, Bennett KJ, Glover S. Postpartum screening for diabetes among Medicaid-eligible South Carolina women with gestational diabetes. Womens Health Issues 2012; 22 (02) e163-e169
• 22 Waters TP, Kim SY, Werner E. et al. Should women with gestational diabetes be screened at delivery hospitalization for type 2 diabetes?. Am J Obstet Gynecol 2020; 222 (01) 73.e1-73.e11